Recent analyses of circulating tumour DNA further supports treatment-selective acquisition of ESR1 mutations,15, 16 and droplet digital PCR has identified ESR1 mutations in a proportion of primary tumours at very low mutant allele frequencies,17 suggesting that endocrine treatments may lead to selection of cancer cells with pre-existing ESR1 mutations. Here, ESR1 is linked to neoplasm.